Evaluates early diagnosis of prostate cancer through NGS testing and family screening, suggesting significant clinical benefits.
Background/Aim: carriership. Materials and Methods: Index patient and family members who have a history of cancer with a familial cancer pedigree were evaluated using a multigene NGS approach. Targeted sequencing was performed on the MGI DNBSEQ-G400 platform using the Twist Bioscience Hereditary Cancer Panel. Results: variant. Conclusion: comprehensive NGS provides tangible clinical benefits by detecting malignancies early in clinically silent carriers.
No takes yet. Share an insight, caveat, or question.
Bilgetekin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: